Each weekly dose of MOUNJARO® 7.5mg KwikPen® is delivered by subcutaneous injection and can be administered at any time of day, with or without food. The abdomen, thigh, and back of the upper arm are all appropriate injection sites; the upper arm is recommended when a second person is assisting with the injection. Rotating the chosen site from one week to the next helps minimize localized skin responses.

Tirzepatide titration opens at 2.5mg once weekly for 4 weeks before advancing to 5mg. The 7.5mg strength represents the next escalation point — an intermediate step between the 5mg level and the 10mg maintenance dose, used when clinical judgment supports a gradual increase rather than a direct advance to the next maintenance threshold. All dose adjustments should be spaced at least 4 weeks apart and guided by the patient’s response and tolerability, with 15mg weekly as the upper limit.

If a weekly dose is missed, it may still be administered within 4 days (96 hours) of the missed dose. Once that window closes, the dose should be skipped and the regular weekly schedule resumed from the next planned date. Insulin co-administration requires a separate injection site; the two products should never be combined at a single site. For information on other MOUNJARO® KwikPen® doses at adjacent points in the titration range, contact the Med Supply Solutions team.

MOUNJARO® (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. This is the approved on-label indication for the MOUNJARO® brand and should be interpreted in accordance with current local prescribing information.

Tirzepatide is the active ingredient in two distinct branded products: MOUNJARO® is indicated for glycemic control in type 2 diabetes, while Zepbound® carries a separate indication for chronic weight management. Licensed professionals should apply this brand-level distinction when making prescribing decisions, structuring procurement, and addressing jurisdiction-specific documentation requirements.

MOUNJARO® must not be used in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or in those with a known serious hypersensitivity reaction to tirzepatide or any excipient in the formulation. Established use in pediatric populations is limited to patients aged 10 and older for the type 2 diabetes indication; safety and efficacy for weight management in patients under 18 have not been established.

Each 0.6 mL dose delivered by the MOUNJARO® 7.5mg KwikPen® supplies 7.5mg of tirzepatide. As a dual agonist, tirzepatide targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, establishing a dual-receptor pathway that distinguishes its clinical profile from traditional mono-GLP-1 receptor agonists.

By co-activating these dual pathways, the medication stimulates glucose-dependent insulin release, dampens glucagon secretion, delays gastric emptying, and curbs appetite alongside overall caloric intake. The drug is presented as a clear, sterile, colorless-to-pale-yellow fluid in a multi-dose pen designed for individual use, with a total volume of 2.4 mL to provide four distinct 0.6 mL doses.

The formulation includes glycerin, phenol, and benzyl alcohol—the latter being a particularly noteworthy excipient given the pen’s multi-use architecture; a full list of ingredients is provided in the product’s prescribing information. Storage requires keeping the pen shielded from light and refrigerating it at 2–8°C (36–46°F), though it can remain unrefrigerated at ambient temperatures up to 30°C (86°F) for no more than 21 days if needed. The solution must never be frozen.

To provide broader clinical context: data from the landmark SURMOUNT-1 trial indicated that patients titrated up to the maximum 15mg maintenance dose experienced an average body weight drop of roughly 21% over 72 weeks. It is critical to emphasize that this high-efficacy benchmark is unique to the 15mg maintenance phase and cannot be generalized to the 7.5mg intermediate titration step.

The KwikPen® is pre-filled with a fixed dose — no dials or manual settings are needed before use. Four once-weekly 0.6 mL subcutaneous injections are available per pen. Before each injection, fit a new needle to the pen; used needles must be discarded after every administration and must not be reused.

With the needle attached, examine the solution in the viewing window before proceeding. The liquid should appear clear, ranging from colorless to slightly yellow. Do not use the pen if the solution looks cloudy, contains floating particles, or shows discoloration of any kind.

Administer the injection subcutaneously, selecting from the abdomen, thigh, or back of the upper arm, and choosing a different area each week. After the injection is complete, remove the needle and dispose of it in a dedicated sharps container. Prescribers should ensure that patients and any caregivers involved in administration have read the manufacturer’s Instructions for Use and the product package leaflet before the first dose is given.

Between uses, store the pen in the refrigerator at 2–8°C. If taken out of refrigeration, the pen must be returned or used within 21 days and kept below 30°C. Protect from direct light and do not allow the pen to freeze.